display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
billiary tract cancer - 1st line (L1)
billiary tract cancer - 1st line (L1)
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-966

Study type: